GSK,NVS,SNY -

. Currency in USD
Stock chart is not supported by your current browser
Previous CloseN/A
OpenN/A
BidN/A x N/A
AskN/A x N/A
Day's RangeN/A - N/A
52 Week Rangeundefined - undefined
VolumeN/A
Avg. VolumeN/A
Market CapN/A
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Top 10 Generic Pharmaceutical Companies In 2017
    Insider Monkey2 hours ago

    Top 10 Generic Pharmaceutical Companies In 2017

    The top 10 generic pharmaceutical companies in 2017 operate in the relatively recession-proof pharmaceuticals industry which is immune from the vagaries of economic cycles. The huge R&D expense and expertise required to develop new medicines is a big entry barrier and the patent laws allow pharmaceuticals companies to make monopolistic profits for a new product […]

  • Reuters3 hours ago

    France's Sanofi pins hopes on new drugs after setbacks

    Sanofi's (SASY.PA) promising pipeline of experimental drugs can help it overcome setbacks including the low uptake of a new cholesterol treatment and concerns about a dengue vaccine, the French pharmaceuticals group said on Wednesday. The world's sixth largest drugmaker, battling to contain the fallout from a safety row in the Philippines over dengue vaccine Dengvaxia, said it expected to file nine medicines for regulatory assessment in the next 18 months. Shares in Sanofi were down 0.77 percent at 1510 GMT.

  • Reuters3 hours ago

    France's Sanofi pins hopes on new drugs after setbacks

    Sanofi's promising pipeline of experimental drugs can help it overcome setbacks including the low uptake of a new cholesterol treatment and concerns about a dengue vaccine, the French pharmaceuticals group said on Wednesday. The world's sixth largest drugmaker, battling to contain the fallout from a safety row in the Philippines over dengue vaccine Dengvaxia, said it expected to file nine medicines for regulatory assessment in the next 18 months. Shares in Sanofi were down 0.77 percent at 1510 GMT.

  • Reuters4 hours ago

    Novartis generics arm says may sell or end some products

    Swiss drugmaker Novartis's Sandoz generics business is in the process of selling or closing some products in the United States, it said on Wednesday. "In response to high price pressure, we are optimizing our U.S. portfolio. "As we continue to refine our portfolio, it is clear that the U.S. market is a very important market for Sandoz and will continue to be in the future," it added.

  • Glaxo's Nucala Label Expansion Application Gets FDA Approval
    Zacks4 hours ago

    Glaxo's Nucala Label Expansion Application Gets FDA Approval

    GlaxoSmithKline's (GSK) application to include treatment of eosinophilic granulomatosis with polyangiitis in Nucala's label was approved by the FDA.

  • Reuters6 hours ago

    Sanofi CEO says M&A targets in oncology are 'very expensive'

    PARIS (Reuters) - Sanofi's Chief Executive Olivier Brandicourt on Wednesday told investors that he considered M&A targets in oncology to be "very expensive". "If you are not starting with ...

  • Reuters13 hours ago

    Did Sanofi, WHO ignore warning signals on dengue vaccine?

    CHICAGO/LONDON (Reuters) - When French drugmaker Sanofi published the results of clinical trials of children given its dengue vaccine two years ago, the overall findings were that it protected against the world's biggest and fastest growing mosquito-borne disease. The study's authors cited two main possibilities: the children had immature immune systems that made the vaccine less protective, or the vaccine itself made them more susceptible to severe disease if they had never had dengue and later became infected. More than two years later, it turns out the latter was the primary factor - a revelation at the end of last month that has triggered alarm among hundreds of thousands of anxious parents in the Philippines, where the vaccine has been given to over 830,000 children.

  • Reuters16 hours ago

    Did Sanofi, WHO ignore warning signals on dengue vaccine?

    CHICAGO/LONDON, Dec 12 (Reuters) - When French drugmaker Sanofi published the results of clinical trials of children given its dengue vaccine two years ago, the overall findings were that it protected against the world's biggest and fastest growing mosquito-borne disease. The study's authors cited two main possibilities: the children had immature immune systems that made the vaccine less protective, or the vaccine itself made them more susceptible to severe disease if they had never had dengue and later became infected. More than two years later, it turns out the latter was the primary factor - a revelation at the end of last month that has triggered alarm among hundreds of thousands of anxious parents in the Philippines, where the vaccine has been given to over 830,000 children.

  • Novartis Announces Positive Data on Sickle Cell Disease Drug
    Zacks20 hours ago

    Novartis Announces Positive Data on Sickle Cell Disease Drug

    Novartis (NVS) announced positive data from a phase II study, SUSTAIN, on pipeline candidate crizanlizumab which deferred the time to first sickle cell pain crisis (SCPC) in patients compared to placebo in key subgroups of adult patients with sickle cell.

  • TheStreet.comyesterday

    Dengue Fever Vaccine Suspension Criticized by Drugmaker Sanofi

    French drug-maker Sanofi contends its Dengue vaccine is good for the country. After 730,000 children were vaccinated, the Philippine government stopped the program on data the drug-maker released that ...

  • Sanofi Wins FDA Approval for Biosimilar of Lilly's Humalog
    Zacksyesterday

    Sanofi Wins FDA Approval for Biosimilar of Lilly's Humalog

    Sanofi's (SNY) Admelog, a follow-on biologic version of Lilly's Humalog, received FDA approval.

  • ASH 2017: CAR-T Wallops Blood Cancer
    Motley Foolyesterday

    ASH 2017: CAR-T Wallops Blood Cancer

    The ability to beat back blood cancer using gene therapy offers a significant opportunity to improve patient treatment.

  • Reutersyesterday

    Sanofi investors hungry for drug progress and deal news

    Sanofi (SASY.PA) still needs to convince markets it can deliver on an exciting and sustainable growth path as it contends with fresh difficulties in its vaccines arm and looks set for another gloomy year in diabetes, investors told Reuters. The French drugmaker holds an "innovation day" on Wednesday to discuss its pipeline of new drugs while it attempts to overcome fallout from a safety row in the Philippines over its dengue vaccine. Shares in Sanofi are trading close to a 10-month low and are down more than 4 percent this year after a 2.2 percent decline last year.

  • Reutersyesterday

    Sanofi investors hungry for drug progress and deal news

    Sanofi still needs to convince markets it can deliver on an exciting and sustainable growth path as it contends with fresh difficulties in its vaccines arm and looks set for another gloomy year in diabetes, investors told Reuters. The French drugmaker holds an "innovation day" on Wednesday to discuss its pipeline of new drugs while it attempts to overcome fallout from a safety row in the Philippines over its dengue vaccine. Shares in Sanofi are trading close to a 10-month low and are down more than 4 percent this year after a 2.2 percent decline last year.

  • Novartis Reports Updated Results from Kymriah's JULIET Study
    Zacks2 days ago

    Novartis Reports Updated Results from Kymriah's JULIET Study

    Novartis (NVS) announced updated results from the JULIET study, which show Kymriah sustained complete responses at six months in adults with relapsed or refractory diffuse large B-cell lymphoma.

  • What's Causing Juno Therapeutics Shares to Tumble 11.9% Today
    Motley Fool2 days ago

    What's Causing Juno Therapeutics Shares to Tumble 11.9% Today

    Investors are selling shares following an important presentation at a key industry conference.

  • Reuters2 days ago

    FDA OKs Sanofi's follow-on biologic of Lilly's diabetes drug Humalog

    The U.S. Food and Drug Administration said on Monday it approved Sanofi SA's Admelog as the first follow-on biologic version of Eli Lilly and Co's fast-acting insulin, Humalog. Admelog, generally taken just before meals, was approved for use in children older than three and adults with type 1 diabetes, as well as adults with type 2 diabetes. Like Humalog, which earned Lilly $696.2 million in the latest quarter, the short-acting drug helps diabetics control blood sugar levels after eating.

  • Reuters2 days ago

    FDA clears Sanofi's follow-on diabetes biologic of Lilly's Humalog

    The U.S. Food and Drug Administration said on Monday it approved Sanofi SA's Admelog as the first follow-on biologic version of Eli Lilly and Co's fast-acting insulin, Humalog. The drug is a short-acting ...

  • Here's Why Bluebird Bio (BLUE) Stock Skyrocketed Today
    Zacks2 days ago

    Here's Why Bluebird Bio (BLUE) Stock Skyrocketed Today

    Shares of Bluebird Bio (BLUE) were up nearly 20% in early morning trading Monday as investors responded to the company's announcement that its CAR-T candidate, bb2121, produced encouraging results in patients with a deadly blood cancer.

  • Barrons.com2 days ago

    Gilead Sciences: Better Data, Better Stock?

    Shares of Gilead Sciences (GILD) are higher on Monday, building on its strength from Friday when it announced its acquisition of Cell Design Labs. Gilead got a boost today from its its presentation at the American Society of Hematology's (ASH) annual meeting, where it and other companies provided update on their CAR-T therapies aimed at cancer. BMO Capital Markets' M. Ian Somaiya wrote that the news was good for Gilead and its peers: Updates from the three leading trials of CD-19 CAR-T therapy in DLBCL (GILD's Yescarta, Juno Therapeutics' (JUNO) JCAR017, Novartis' (NVS) Kymriah) raise the bar yet again for CAR-Ts.

  • 3 High-Yield Dividend Stocks to Buy in 2018
    Motley Fool2 days ago

    3 High-Yield Dividend Stocks to Buy in 2018

    These 3 Big Pharma stocks may be worth adding to your portfolio in 2018.

  • MarketWatch2 days ago

    These defensive stocks make the cut as one of Morgan Stanley’s key picks for 2018

    Switzerland’s stocks are changing hands below their typical premium, the Swiss franc appears poised to slide further against the euro, and earnings growth looks good.

  • Glaxo's New Pharma Head Looks to Move Fast, Especially in Cancer
    Bloomberg2 days ago

    Glaxo's New Pharma Head Looks to Move Fast, Especially in Cancer

    GlaxoSmithKline Plc, the U.K.’s biggest drugmaker, signaled it will look to speed development of an experimental cancer treatment as part of its ambition to expand in oncology just two years after selling ...

  • Regeneron (REGN) Down 8.3% Since Earnings Report: Can It Rebound?
    Zacks2 days ago

    Regeneron (REGN) Down 8.3% Since Earnings Report: Can It Rebound?

    Regeneron (REGN) reported earnings more than 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Reuters3 days ago

    Novartis CAR-T therapy leads to durable response in lymphoma study

    Patients with an advanced form of an aggressive blood cancer who had initially responded to Novartis' new type of gene-modifying immunotherapy continued to respond at least six months after treatment, according to updated data released at a medical meeting on Sunday. Among 46 patients with at least six months of follow-up after treatment with Novartis' Kymriah for diffuse large B-cell lymphoma (DLBCL), 30 percent still had a complete response, meaning no detectable sign of cancer, with another 7 percent achieving a partial response.